Evidence map›Paper›PMID 31966448›Full record

ArticleInternational journal of clinical and experimental pathology2017

Bone morphogenetic protein 9 is a potential tumor suppressor in osteosarcoma.

Jinghao Liang, Jing Zhang, Fan Chen, Zhengjun Lian, Yalu Dong, Ning Lu, Yong Jia

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jinghao LiangDepartment of Orthopedics, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Jing ZhangDepartment of Oncology, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Fan ChenDepartment of Oncology, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Zhengjun LianDepartment of Oncology, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Yalu DongDepartment of Oncology, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Ning LuDepartment of Oncology, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Yong JiaDepartment of Orthopedics, General Hospital of Xinjiang Military Command of PLA Urumqi, P. R. China.
Urumqi General Hospital of PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transforming growth factor-β (TGF-β) is known to promote tumor migration and invasion. Bone morphogenetic proteins (BMPs) are members of the TGF-β family expressed in a variety of human carcinoma cell lines. Although accumulating evidence has shown that BMP9 plays important roles in the regulation of various cellular processes, the function of BMP9 in clinical osteosarcoma remains to be explored. In this study, BMP9 expression was analyzed in 55 osteosarcoma patient samples and their matching, distant non-cancerous tissues. And the roles of BMP9 in osteosarcoma cell proliferation, apoptosis and cell cycle were also examined. Our results showed that different expression level of BMP9 was detected in all osteosarcoma samples while no expression in normal tissues. Surprisingly, there was a negative association between the expression level of BMP9 and osteosarcoma grade, with low level of BMP9 being found in high histological grade osteosarcoma. Knockdown of BMP9 accelerated the proliferation of MG63, SaOS-2, and U2OS cells. BMP9 overexpression, however, induced cell apoptosis in U2OS cells. Together, these results indicated that BMP9 plays a pivotal role in osteosarcoma. Future studies defining the mechanism of BMP9 effect may lead to novel therapeutic approaches for osteosarcoma.

Indexed as

BMP9osteosarcomatumor suppressor

Identifiers

PMID31966448
PMCPMC6965842
OpenAlexW3012675480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.